首页 > 最新文献

Acta Psychiatrica Scandinavica最新文献

英文 中文
Augmentation with prazosin for patients with depression and a history of trauma: A randomised, double-blind, placebo-controlled study. 哌唑嗪对有创伤史的抑郁症患者的辅助治疗:随机、双盲、安慰剂对照研究。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-09-27 DOI: 10.1111/acps.13763
Ping Guo, Yong Xu, Liang Lv, Min Feng, Yu Fang, Shanfei Cheng, Xiaoqing Xiao, Juanjuan Huang, Wei Sheng, Shikai Wang, Huanxin Chen

Introduction: Depression with a history of trauma often responds poorly to conventional antidepressants and has a poor prognosis. Prazosin, an α1-adrenoceptor blocker, has shown promise in treating post-traumatic stress disorder symptoms, particularly nightmares. Its potential in treating depression with trauma history warrants investigation.

Aims of the study: This randomised, double-blind, placebo-controlled study aimed to investigate the efficacy and tolerability of low-dose prazosin (0.5-1 mg/day) as an augmentation strategy in patients with depression and a history of trauma. We sought to determine if prazosin could provide rapid symptom improvement and enhance overall treatment response compared to placebo in this difficult-to-treat patient population.

Methods: This randomised, double-blind, placebo-controlled clinical study included 59 patients with first-episode or recurrent unipolar or bipolar depression. After basic antidepressant treatment, they were randomly assigned to a prazosin (0.5-1 mg/day) or placebo group for a 6-week double-blind controlled study. The Montgomery-Åsberg Depression Rating Scale, 17-item Hamilton Depression Scale (HAMD-17), and Hamilton Anxiety Scale (HAMA) were used to evaluate efficacy.

Results: There were no significant differences in the results of the demographic and clinical symptom assessment between the two groups (p > 0.05). The difference between the HAMD-17 and HAMA scores was statistically significant after 3 days of treatment (p < 0.05). The difference in response rate between the two groups was statistically significant after week 4 of treatment (end of week 4, 56.7% vs. 24.1%, p = 0.011; end of week 6, 80.0% vs. 48.3%, p = 0.011). The incidence of adverse reactions in the prazosin and placebo groups was 20.0% and 24.1%, respectively, with no statistically significant differences (p > 0.05); however, the prazosin group had a lower incidence of sleeplessness or nightmares (3.3% vs. 20.7%, p = 0.039) but a higher incidence of orthostatic hypotension (16.7% vs. 0%, p = 0.007). The severity of orthostatic hypotension was mild to moderate.

Conclusion: Low-dose prazosin can effectively improve the emotional symptoms of patients with depression and a history of trauma, and the common adverse reaction is mild-to-moderate orthostatic hypotension.

Clinical trial registration: ChiCTR2200063642.

简介有创伤史的抑郁症患者对传统抗抑郁药的反应通常很差,预后也很差。哌唑嗪是一种α1-肾上腺素受体阻滞剂,在治疗创伤后应激障碍症状(尤其是噩梦)方面显示出良好的前景。它在治疗有创伤史的抑郁症方面的潜力值得研究:这项随机、双盲、安慰剂对照研究旨在调查小剂量哌唑嗪(0.5-1 毫克/天)作为抑郁症和创伤史患者的增强策略的疗效和耐受性。我们试图确定,与安慰剂相比,哌唑嗪能否在这一难以治疗的患者群体中迅速改善症状并提高总体治疗反应:这项随机、双盲、安慰剂对照临床研究纳入了59名首次发病或复发的单相或双相抑郁症患者。经过基本抗抑郁治疗后,他们被随机分配到哌唑嗪(0.5-1毫克/天)或安慰剂组,进行为期6周的双盲对照研究。研究采用蒙哥马利-奥斯伯格抑郁评定量表、17项汉密尔顿抑郁量表(HAMD-17)和汉密尔顿焦虑量表(HAMA)来评估疗效:结果:两组患者的人口统计学和临床症状评估结果无明显差异(P>0.05)。治疗3天后,HAMD-17和HAMA评分之间的差异有统计学意义(P 0.05);然而,哌唑嗪组失眠或噩梦的发生率较低(3.3% vs. 20.7%,P = 0.039),但直立性低血压的发生率较高(16.7% vs. 0%,P = 0.007)。正性低血压的严重程度为轻度至中度:结论:小剂量哌唑嗪能有效改善抑郁症和外伤史患者的情绪症状,常见的不良反应为轻中度正张性低血压:临床试验注册:ChiCTR2200063642。
{"title":"Augmentation with prazosin for patients with depression and a history of trauma: A randomised, double-blind, placebo-controlled study.","authors":"Ping Guo, Yong Xu, Liang Lv, Min Feng, Yu Fang, Shanfei Cheng, Xiaoqing Xiao, Juanjuan Huang, Wei Sheng, Shikai Wang, Huanxin Chen","doi":"10.1111/acps.13763","DOIUrl":"10.1111/acps.13763","url":null,"abstract":"<p><strong>Introduction: </strong>Depression with a history of trauma often responds poorly to conventional antidepressants and has a poor prognosis. Prazosin, an α1-adrenoceptor blocker, has shown promise in treating post-traumatic stress disorder symptoms, particularly nightmares. Its potential in treating depression with trauma history warrants investigation.</p><p><strong>Aims of the study: </strong>This randomised, double-blind, placebo-controlled study aimed to investigate the efficacy and tolerability of low-dose prazosin (0.5-1 mg/day) as an augmentation strategy in patients with depression and a history of trauma. We sought to determine if prazosin could provide rapid symptom improvement and enhance overall treatment response compared to placebo in this difficult-to-treat patient population.</p><p><strong>Methods: </strong>This randomised, double-blind, placebo-controlled clinical study included 59 patients with first-episode or recurrent unipolar or bipolar depression. After basic antidepressant treatment, they were randomly assigned to a prazosin (0.5-1 mg/day) or placebo group for a 6-week double-blind controlled study. The Montgomery-Åsberg Depression Rating Scale, 17-item Hamilton Depression Scale (HAMD-17), and Hamilton Anxiety Scale (HAMA) were used to evaluate efficacy.</p><p><strong>Results: </strong>There were no significant differences in the results of the demographic and clinical symptom assessment between the two groups (p > 0.05). The difference between the HAMD-17 and HAMA scores was statistically significant after 3 days of treatment (p < 0.05). The difference in response rate between the two groups was statistically significant after week 4 of treatment (end of week 4, 56.7% vs. 24.1%, p = 0.011; end of week 6, 80.0% vs. 48.3%, p = 0.011). The incidence of adverse reactions in the prazosin and placebo groups was 20.0% and 24.1%, respectively, with no statistically significant differences (p > 0.05); however, the prazosin group had a lower incidence of sleeplessness or nightmares (3.3% vs. 20.7%, p = 0.039) but a higher incidence of orthostatic hypotension (16.7% vs. 0%, p = 0.007). The severity of orthostatic hypotension was mild to moderate.</p><p><strong>Conclusion: </strong>Low-dose prazosin can effectively improve the emotional symptoms of patients with depression and a history of trauma, and the common adverse reaction is mild-to-moderate orthostatic hypotension.</p><p><strong>Clinical trial registration: </strong>ChiCTR2200063642.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"142-151"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Not all types of depressed patients who persist with their antidepressant treatment improve in side effect complaints: A comparison of treatment completers and dropouts in the STAR*D trial. 并非所有类型的抑郁症患者在坚持接受抗抑郁治疗后,副作用症状都有所改善:STAR*D试验中完成治疗者与退出治疗者的比较。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-10-03 DOI: 10.1111/acps.13764
Thomas T Kim, Colin Xu

Introduction: There is a "traditional belief" that antidepressant side effect complaints improve with medication persistence; however, support for this theory has remained inconclusive. We aimed to examine if side effect complaints improved over time by modeling the relationship between side effect complaints and time at dropout for patients receiving citalopram during the first level of acute treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Methods: We categorized the 2833 patients into five patterns by week of dropout. We used pattern-mixture modeling to model change in side effect complaints (frequency, intensity, and burden) over the 12-week course of treatment, while accounting for attrition and depressive severity. Using post-hoc linear contrasts, we compared the attrition patterns with the completers' pattern for severity of side effect complaints at each respective last visit prior to dropout as well as averaged side effect complaints across the duration of treatment. We also reported frequencies and tolerability of side effects for nine organ/function systems over the course of treatment.

Results: Patients who dropped out early exhibited worsening side effect burden and patients who dropped out later showed improvements in side effect frequency and intensity. Treatment completers improved in all side effect complaints over the course of treatment. Early attrition patterns had more severe side effect complaints for both tests of post-hoc linear contrasts than later attrition patterns and completers.

Conclusions: Side effect complaints from antidepressant treatment improve over time, but only for some types of patients. As a precaution for early dropout, clinicians should monitor patients who exhibit worsening and more severe side effect complaints-especially in the first 6 weeks of antidepressant treatment. In addition, clinicians may want to consider changing the type of treatment early on for these patients, rather than encouraging them to persist with their current medication.

简介有一种 "传统观念 "认为,抗抑郁药物的副作用投诉会随着服药时间的延长而改善;然而,对这一理论的支持仍然没有定论。我们的目的是通过模拟 "缓解抑郁的序贯治疗替代方案(STAR*D)"试验中接受西酞普兰治疗的患者在第一级急性治疗期间的副作用投诉与停药时间之间的关系,来研究副作用投诉是否会随着时间的推移而改善:我们将 2833 名患者按辍药周数分为五种模式。我们使用模式-混合模型来模拟12周疗程中副作用主诉(频率、强度和负担)的变化,同时考虑到自然减员和抑郁严重程度。通过事后线性对比,我们比较了自然减员模式和完成者模式在辍学前最后一次就诊时的副作用症状严重程度,以及整个治疗期间的平均副作用症状。我们还报告了治疗过程中九个器官/功能系统的副作用频率和耐受性:结果:早期退出治疗的患者副作用负担加重,而后期退出治疗的患者副作用频率和强度有所改善。在治疗过程中,完成治疗者的所有副作用症状都有所改善。在两次事后线性对比测试中,早期退出者的副作用症状都比后期退出者和治疗完成者严重:结论:随着时间的推移,抗抑郁治疗的副作用症状会有所改善,但仅限于某些类型的患者。为防止患者过早退出治疗,临床医生应监测那些副作用症状加重的患者,尤其是在抗抑郁治疗的前 6 周。此外,临床医生可能会考虑尽早为这些患者更换治疗类型,而不是鼓励他们坚持使用现有药物。
{"title":"Not all types of depressed patients who persist with their antidepressant treatment improve in side effect complaints: A comparison of treatment completers and dropouts in the STAR*D trial.","authors":"Thomas T Kim, Colin Xu","doi":"10.1111/acps.13764","DOIUrl":"10.1111/acps.13764","url":null,"abstract":"<p><strong>Introduction: </strong>There is a \"traditional belief\" that antidepressant side effect complaints improve with medication persistence; however, support for this theory has remained inconclusive. We aimed to examine if side effect complaints improved over time by modeling the relationship between side effect complaints and time at dropout for patients receiving citalopram during the first level of acute treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.</p><p><strong>Methods: </strong>We categorized the 2833 patients into five patterns by week of dropout. We used pattern-mixture modeling to model change in side effect complaints (frequency, intensity, and burden) over the 12-week course of treatment, while accounting for attrition and depressive severity. Using post-hoc linear contrasts, we compared the attrition patterns with the completers' pattern for severity of side effect complaints at each respective last visit prior to dropout as well as averaged side effect complaints across the duration of treatment. We also reported frequencies and tolerability of side effects for nine organ/function systems over the course of treatment.</p><p><strong>Results: </strong>Patients who dropped out early exhibited worsening side effect burden and patients who dropped out later showed improvements in side effect frequency and intensity. Treatment completers improved in all side effect complaints over the course of treatment. Early attrition patterns had more severe side effect complaints for both tests of post-hoc linear contrasts than later attrition patterns and completers.</p><p><strong>Conclusions: </strong>Side effect complaints from antidepressant treatment improve over time, but only for some types of patients. As a precaution for early dropout, clinicians should monitor patients who exhibit worsening and more severe side effect complaints-especially in the first 6 weeks of antidepressant treatment. In addition, clinicians may want to consider changing the type of treatment early on for these patients, rather than encouraging them to persist with their current medication.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"152-162"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotics or Mood Stabilizers in Bipolar Disorder: Towards Evidence-Based Personalised Medicine.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-12-16 DOI: 10.1111/acps.13780
Marie Tournier
{"title":"Antipsychotics or Mood Stabilizers in Bipolar Disorder: Towards Evidence-Based Personalised Medicine.","authors":"Marie Tournier","doi":"10.1111/acps.13780","DOIUrl":"10.1111/acps.13780","url":null,"abstract":"","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"107-108"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Early Intervention for Early Psychosis on Suicidal Behavior-A Meta-Analysis. 早期精神病早期干预对自杀行为的影响--Meta 分析。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-11-27 DOI: 10.1111/acps.13773
Elkhan Tahmazov, Jordan Bosse, Benjamin Glemain, Patrice Nabbe, Morgane Guillou, Athéna Blachier, Michel Walter, Christophe Lemey

Introduction: Early-onset psychotic disorders include the prodromal phase and the first-episode psychosis (FEP). They constitute a high-risk period for suicidal behavior. Early intervention for psychosis (EIP) consists of intervening as early as possible. The effectiveness of early intervention on overall prognosis has been reported in numerous studies, and EIP services are emerging worldwide. Several authors report an improvement in suicidal behavior, but no study has looked at all the data.

Aims of the study: The aim of work is to study whether early intervention for psychosis has an impact on deaths by suicide and suicide attempts, and study which intervention methods have an impact on suicidal behavior.

Methodology: By respecting the PRISMA criteria, previously declared on PROSPERO, by exploring 5 medical databases (PubMed, Cochrane, PsycINFO, Scopus, Embase), from their creation dates, published until 20/02/2023, in English, we carried out a meta-analysis. The articles selected had to deal with the EIP and deaths by suicide or suicide attempts. Our primary outcome is the deaths by suicide and the secondary outcome the suicide attempt.

Results: The exhaustive search identified a total of 2310 references. Nine articles were included. Their intervention modalities were pharmacotherapy, psychotherapy, case-management, or related services, and psycho-social therapies. Our meta-analysis shows that early intervention for early-onset psychotic disorders is associated with a statistically significant reduction by a third in deaths by suicide (ORa = 0.66 (0.49-0.88), p = 0.005) and by a third in suicide attempts (ORa = 0.66 (0.50-0.86), p = 0.002), with non-significant heterogeneity. Sensitivity analyses excluding the study with statistical difficulties due to the absence of an event and studies with a high risk of bias point in the same direction, that is a statistically significant reduction and non-significant heterogeneity.

Conclusion: The literature shows that early intervention programs are associated with positive impact on deaths by suicide and suicide attempt. This is the first meta-analysis of early intervention in early psychotic disorders and its impact on suicidal risk. The deployment of EIP should be supported worldwide in order to intervene as early as possible and prevent the risk of suicide.

Trial registration: PROSPERO CRD42022366976.

简介早发精神病包括前驱期和首发精神病(FEP)。它们是自杀行为的高危期。精神病早期干预(EIP)包括尽早干预。许多研究都报道了早期干预对总体预后的有效性,而且 EIP 服务正在全球范围内兴起。一些作者报告称,自杀行为有所改善,但还没有研究对所有数据进行调查:工作目的:研究精神病早期干预是否会对自杀死亡和自杀未遂产生影响,并研究哪些干预方法会对自杀行为产生影响:通过遵守 PRISMA 标准(之前已在 PROSPERO 上声明),探索 5 个医学数据库(PubMed、Cochrane、PsycINFO、Scopus、Embase)中自创建之日起至 2023 年 2 月 20 日发表的英文文献,我们进行了一项荟萃分析。所选文章必须涉及 EIP 和自杀或自杀未遂死亡。我们的主要结果是自杀死亡,次要结果是自杀未遂:通过详尽搜索,共找到 2310 篇参考文献。九篇文章被纳入其中。其干预方式包括药物疗法、心理疗法、个案管理或相关服务以及社会心理疗法。我们的荟萃分析表明,对早发性精神病的早期干预可使自杀死亡人数减少三分之一(ORa = 0.66 (0.49-0.88),p = 0.005),自杀未遂人数减少三分之一(ORa = 0.66 (0.50-0.86),p = 0.002),异质性不显著。敏感性分析排除了因未发生事件而导致统计困难的研究和偏倚风险较高的研究,结果指向相同的方向,即在统计上显著降低,异质性不显著:文献显示,早期干预计划对自杀死亡和自杀未遂有积极影响。这是首次对早期精神障碍的早期干预及其对自杀风险的影响进行荟萃分析。为了尽早干预并预防自杀风险,EIP的部署应在全球范围内得到支持:试验注册:PREMCOCRD42022366976。
{"title":"Impact of Early Intervention for Early Psychosis on Suicidal Behavior-A Meta-Analysis.","authors":"Elkhan Tahmazov, Jordan Bosse, Benjamin Glemain, Patrice Nabbe, Morgane Guillou, Athéna Blachier, Michel Walter, Christophe Lemey","doi":"10.1111/acps.13773","DOIUrl":"10.1111/acps.13773","url":null,"abstract":"<p><strong>Introduction: </strong>Early-onset psychotic disorders include the prodromal phase and the first-episode psychosis (FEP). They constitute a high-risk period for suicidal behavior. Early intervention for psychosis (EIP) consists of intervening as early as possible. The effectiveness of early intervention on overall prognosis has been reported in numerous studies, and EIP services are emerging worldwide. Several authors report an improvement in suicidal behavior, but no study has looked at all the data.</p><p><strong>Aims of the study: </strong>The aim of work is to study whether early intervention for psychosis has an impact on deaths by suicide and suicide attempts, and study which intervention methods have an impact on suicidal behavior.</p><p><strong>Methodology: </strong>By respecting the PRISMA criteria, previously declared on PROSPERO, by exploring 5 medical databases (PubMed, Cochrane, PsycINFO, Scopus, Embase), from their creation dates, published until 20/02/2023, in English, we carried out a meta-analysis. The articles selected had to deal with the EIP and deaths by suicide or suicide attempts. Our primary outcome is the deaths by suicide and the secondary outcome the suicide attempt.</p><p><strong>Results: </strong>The exhaustive search identified a total of 2310 references. Nine articles were included. Their intervention modalities were pharmacotherapy, psychotherapy, case-management, or related services, and psycho-social therapies. Our meta-analysis shows that early intervention for early-onset psychotic disorders is associated with a statistically significant reduction by a third in deaths by suicide (ORa = 0.66 (0.49-0.88), p = 0.005) and by a third in suicide attempts (ORa = 0.66 (0.50-0.86), p = 0.002), with non-significant heterogeneity. Sensitivity analyses excluding the study with statistical difficulties due to the absence of an event and studies with a high risk of bias point in the same direction, that is a statistically significant reduction and non-significant heterogeneity.</p><p><strong>Conclusion: </strong>The literature shows that early intervention programs are associated with positive impact on deaths by suicide and suicide attempt. This is the first meta-analysis of early intervention in early psychotic disorders and its impact on suicidal risk. The deployment of EIP should be supported worldwide in order to intervene as early as possible and prevent the risk of suicide.</p><p><strong>Trial registration: </strong>PROSPERO CRD42022366976.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"127-141"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social Support, Delivery Mode, and Cultural Factors in Twin Parents' Postpartum Depression: A Response to Egsgaard et al.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-12-01 DOI: 10.1111/acps.13775
Yu-Ren Wen, Lien-Chung Wei

Background: Egsgaard et al. (2024) highlight the temporal patterns of postpartum depression (PPD) risk in twin parents versus singleton parents. However, additional factors such as social support systems, delivery mode, and cultural influences require exploration.

Purpose: To discuss the role of structured postpartum care, cesarean sections, and mother-infant bonding in moderating PPD risk, especially within cultural contexts.

Conclusion: These factors may explain the gender-specific temporal patterns observed by Egsgaard et al. Future research should integrate sociocultural and clinical variables to inform interventions for twin parents at risk of PPD.

{"title":"Social Support, Delivery Mode, and Cultural Factors in Twin Parents' Postpartum Depression: A Response to Egsgaard et al.","authors":"Yu-Ren Wen, Lien-Chung Wei","doi":"10.1111/acps.13775","DOIUrl":"10.1111/acps.13775","url":null,"abstract":"<p><strong>Background: </strong>Egsgaard et al. (2024) highlight the temporal patterns of postpartum depression (PPD) risk in twin parents versus singleton parents. However, additional factors such as social support systems, delivery mode, and cultural influences require exploration.</p><p><strong>Purpose: </strong>To discuss the role of structured postpartum care, cesarean sections, and mother-infant bonding in moderating PPD risk, especially within cultural contexts.</p><p><strong>Conclusion: </strong>These factors may explain the gender-specific temporal patterns observed by Egsgaard et al. Future research should integrate sociocultural and clinical variables to inform interventions for twin parents at risk of PPD.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"173-174"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk and timing of postpartum depression in parents of twins compared to parents of singletons. 与单胎父母相比,双胞胎父母产后抑郁的风险和时间。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-02-01 Epub Date: 2024-10-25 DOI: 10.1111/acps.13766
Sofie Egsgaard, Mette Bliddal, Lars Christian Lund, Simone N Vigod, Trine Munk-Olsen

Background: Parents of twins appear to be at increased risk of postpartum depression (PPD), yet little is known about the magnitude and timing of onset in the postpartum period compared to singleton parents.

Methods: We conducted a cohort study using the Danish nationwide health registers. We defined a study population of parents that is, mothers and fathers of all twin and singleton livebirths between 1997 and 2019. Postpartum depression was defined as incident depression diagnosis or a redeemed antidepressant prescription from childbirth through 365 days postpartum. We performed a parametric time-to-event analysis based on Poisson regression. The time scale was time since birth, modeled using restricted cubic splines. From this we estimated the hazard ratio (HR) representing the momentary risk, and the cumulative risk ratio (RR) over the first year postpartum, in twin compared to singleton parents.

Results: The study population was based on 27,095 twin and 1,350,046 singleton births. In adjusted analyses, the HR of twins compared to singletons was highest around 2 months postpartum (HR 1.28, 95% CI 1.10-1.49) for mothers, and around 6 months (1.20, 95% CI 1.02-1.42) for fathers. The 6 months adjusted cumulative RR of PPD in twins compared to singletons was 1.24 (95% CI 1.10-1.40) for mothers and 1.11 (95% CI 0.95-1.30) for fathers.

Conclusions: Twin mothers had increased risk of PPD compared to singleton mothers, which was driven by an immediate increase after childbirth. The risk among twin fathers was not increased immediately after childbirth, but we found slightly elevated risk around 6 months postpartum. This could suggest diverse patterns of PPD symptomatology in twin parents compared to singleton parents and between mothers and fathers. Our findings underline parents of twins as a potentially vulnerable group to PPD and emphasize the need for increased awareness of their mental health.

背景:双胞胎父母患产后抑郁症(PPD)的风险似乎更高,但与单胎父母相比,人们对双胞胎父母产后抑郁症的程度和发病时间知之甚少:我们利用丹麦全国健康登记册进行了一项队列研究。方法:我们利用丹麦全国健康登记册进行了一项队列研究。我们定义了一个父母研究人群,即 1997 年至 2019 年间所有双胞胎和单胎活产婴儿的母亲和父亲。产后抑郁症的定义是:从分娩到产后 365 天内,诊断出抑郁症或开具过抗抑郁药处方。我们在泊松回归的基础上进行了参数时间事件分析。时间尺度为出生后的时间,使用受限立方样条进行建模。由此,我们估算出了双胎父母与单胎父母相比,代表瞬间风险的危险比(HR)和产后第一年的累积风险比(RR):研究对象包括 27,095 名双胞胎和 1,350,046 名单胎。在调整分析中,双胞胎与单胎相比,母亲在产后 2 个月左右的 HR 最高(HR 1.28,95% CI 1.10-1.49),父亲在产后 6 个月左右的 HR 最高(1.20,95% CI 1.02-1.42)。双胞胎与单胎相比,母亲患 PPD 的 6 个月调整累积 RR 为 1.24(95% CI 1.10-1.40),父亲为 1.11(95% CI 0.95-1.30):与单胎母亲相比,双胞胎母亲罹患PPD的风险更高,这主要是由于分娩后罹患PPD的风险立即增加。双胞胎父亲的风险在产后没有立即增加,但我们发现在产后6个月左右风险略有增加。这可能表明,与单胎父母相比,双胞胎父母以及母亲和父亲之间的 PPD 症状模式各不相同。我们的研究结果强调了双胞胎父母是潜在的 PPD 易感人群,并强调需要提高对他们心理健康的认识。
{"title":"Risk and timing of postpartum depression in parents of twins compared to parents of singletons.","authors":"Sofie Egsgaard, Mette Bliddal, Lars Christian Lund, Simone N Vigod, Trine Munk-Olsen","doi":"10.1111/acps.13766","DOIUrl":"10.1111/acps.13766","url":null,"abstract":"<p><strong>Background: </strong>Parents of twins appear to be at increased risk of postpartum depression (PPD), yet little is known about the magnitude and timing of onset in the postpartum period compared to singleton parents.</p><p><strong>Methods: </strong>We conducted a cohort study using the Danish nationwide health registers. We defined a study population of parents that is, mothers and fathers of all twin and singleton livebirths between 1997 and 2019. Postpartum depression was defined as incident depression diagnosis or a redeemed antidepressant prescription from childbirth through 365 days postpartum. We performed a parametric time-to-event analysis based on Poisson regression. The time scale was time since birth, modeled using restricted cubic splines. From this we estimated the hazard ratio (HR) representing the momentary risk, and the cumulative risk ratio (RR) over the first year postpartum, in twin compared to singleton parents.</p><p><strong>Results: </strong>The study population was based on 27,095 twin and 1,350,046 singleton births. In adjusted analyses, the HR of twins compared to singletons was highest around 2 months postpartum (HR 1.28, 95% CI 1.10-1.49) for mothers, and around 6 months (1.20, 95% CI 1.02-1.42) for fathers. The 6 months adjusted cumulative RR of PPD in twins compared to singletons was 1.24 (95% CI 1.10-1.40) for mothers and 1.11 (95% CI 0.95-1.30) for fathers.</p><p><strong>Conclusions: </strong>Twin mothers had increased risk of PPD compared to singleton mothers, which was driven by an immediate increase after childbirth. The risk among twin fathers was not increased immediately after childbirth, but we found slightly elevated risk around 6 months postpartum. This could suggest diverse patterns of PPD symptomatology in twin parents compared to singleton parents and between mothers and fathers. Our findings underline parents of twins as a potentially vulnerable group to PPD and emphasize the need for increased awareness of their mental health.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":"163-172"},"PeriodicalIF":5.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Altered Functional Connectivity of Prefrontal Cortex-Related Circuitry and Trait Impulsivity in Patients With Bipolar Disorder and History of Suicide Attempts.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-01-05 DOI: 10.1111/acps.13786
Mao-Hsuan Huang, Yi-Hsuan Kuan, Pei-Chi Tu, Wan-Chen Chang, Yee-Lam E Chan, Tung-Ping Su

Background: The neurobiological basis of impulsivity and its role in suicide attempt (SA) in BD remains underexplored. This study aimed to examine the functional connectivity (FC) within the prefrontal cortex (PFC) in BD patients with and without a history of SA, focusing on the role of trait impulsivity.

Methods: Seventy-two euthymic BD patients (34 with a history of SA, BDSA; and 38 without, BDNS) and 55 age- and sex-matched healthy controls underwent resting-state functional MRI. FC analyses were conducted on four PFC regions: superior frontal gyrus (SFG), middle frontal gyrus (MFG), inferior frontal gyrus (IFG), and orbitofrontal cortex (OFC). Trait impulsivity was assessed using the Barratt Impulsiveness Scale (BIS-11), and its association with FC was analyzed using a general linear model, adjusting for demographic and clinical variables.

Results: BDSA had higher trait impulsivity than BDNS and the controls. BDSA exhibited reduced FC between the PFC and sensorimotor (postcentral and precentral gyri) and thalamic regions compared to BDNS. These reductions in FC of the fronto-thalamic and fronto-sensorimotor circuits were significantly associated with higher trait impulsivity scores.

Conclusion: The findings highlight specific PFC-based FC alterations associated with suicide attempts and trait impulsivity in BD, offering potential neurobiological markers for suicide risk in this population.

{"title":"Altered Functional Connectivity of Prefrontal Cortex-Related Circuitry and Trait Impulsivity in Patients With Bipolar Disorder and History of Suicide Attempts.","authors":"Mao-Hsuan Huang, Yi-Hsuan Kuan, Pei-Chi Tu, Wan-Chen Chang, Yee-Lam E Chan, Tung-Ping Su","doi":"10.1111/acps.13786","DOIUrl":"https://doi.org/10.1111/acps.13786","url":null,"abstract":"<p><strong>Background: </strong>The neurobiological basis of impulsivity and its role in suicide attempt (SA) in BD remains underexplored. This study aimed to examine the functional connectivity (FC) within the prefrontal cortex (PFC) in BD patients with and without a history of SA, focusing on the role of trait impulsivity.</p><p><strong>Methods: </strong>Seventy-two euthymic BD patients (34 with a history of SA, BDSA; and 38 without, BDNS) and 55 age- and sex-matched healthy controls underwent resting-state functional MRI. FC analyses were conducted on four PFC regions: superior frontal gyrus (SFG), middle frontal gyrus (MFG), inferior frontal gyrus (IFG), and orbitofrontal cortex (OFC). Trait impulsivity was assessed using the Barratt Impulsiveness Scale (BIS-11), and its association with FC was analyzed using a general linear model, adjusting for demographic and clinical variables.</p><p><strong>Results: </strong>BDSA had higher trait impulsivity than BDNS and the controls. BDSA exhibited reduced FC between the PFC and sensorimotor (postcentral and precentral gyri) and thalamic regions compared to BDNS. These reductions in FC of the fronto-thalamic and fronto-sensorimotor circuits were significantly associated with higher trait impulsivity scores.</p><p><strong>Conclusion: </strong>The findings highlight specific PFC-based FC alterations associated with suicide attempts and trait impulsivity in BD, offering potential neurobiological markers for suicide risk in this population.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery and Recurrence From Major Depression in Adolescence and Adulthood.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-01-05 DOI: 10.1111/acps.13785
Adrian E Desai Boström, Thomas Cars, Clara Hellner, Johan Lundberg

Objective: The study aimed to estimate 5-year recurrence rates of first-episode major depressive disorder (MDD) and assess the impact of adolescence on recurrence likelihood after the first episode, compared to adults.

Methods: A pre-registered retrospective cohort study that utilized epidemiological data from the Stockholm MDD Cohort (1997-2018), including all individuals registered with a depression diagnosis in Region Stockholm from 2010 to 2018. This dataset combines longitudinal information from primary and secondary care, socioeconomic data, drug dispensations, psychotherapy sessions, brain stimulation treatments, and inpatient treatment. The study included 9124 individuals (1727 adolescents aged 13-17 and 7397 adults aged 18-40) who experienced their first MDD episode between 2011 and 2012, with at least three months of remission. Propensity score weighting balanced cohorts for biological sex, socioeconomic status, depression severity, psychiatric comorbidities, and treatments.

Results: The 5-year recurrence rates were 46.1% for adolescents and 49.0% for adults. The study had over 80% power to detect a minimum absolute difference in recurrence rates of approximately 5.5 percentage points. No significant difference in recurrence likelihood (p = 0.364) or time from remission to recurrence (median 379 days for adolescents, 326 days for adults, p = 0.836) was found between groups. Findings were consistent across bootstrap replicates and sensitivity analyses with extended remission periods.

Conclusions: Approximately half of individuals with a first MDD episode experience recurrence within five years. Recurrence rates were higher than expected for adults but consistent with expectations for adolescents. The study underscores the need for relapse prevention from adolescence through adulthood and indicates a similar clinical course of MDD across age groups.

研究目的该研究旨在估算首次发病的重度抑郁症(MDD)的5年复发率,并评估与成人相比,青春期对首次发病后复发可能性的影响:这是一项预先登记的回顾性队列研究,利用了斯德哥尔摩 MDD 队列(1997-2018 年)的流行病学数据,包括 2010 年至 2018 年在斯德哥尔摩地区登记的所有抑郁症诊断患者。该数据集结合了来自初级和二级护理的纵向信息、社会经济数据、药物配给、心理治疗疗程、脑刺激治疗和住院治疗。研究纳入了 9124 人(1727 名 13-17 岁的青少年和 7397 名 18-40 岁的成年人),他们都是在 2011 年至 2012 年期间首次出现 MDD 病情,并至少缓解了三个月。倾向得分加权平衡了生物性别、社会经济地位、抑郁严重程度、精神并发症和治疗方法等因素:青少年和成人的5年复发率分别为46.1%和49.0%。该研究的功率超过 80%,可检测出复发率的最小绝对差异约为 5.5 个百分点。在复发可能性(p = 0.364)或从缓解到复发的时间(青少年中位数为 379 天,成人中位数为 326 天,p = 0.836)方面,组间没有发现明显差异。这些结果在引导复制和延长缓解期的敏感性分析中是一致的:结论:约有一半的首次 MDD 患者在五年内复发。复发率高于对成人的预期,但与对青少年的预期一致。这项研究强调了从青春期到成年期预防复发的必要性,并表明不同年龄组的 MDD 临床病程相似。
{"title":"Recovery and Recurrence From Major Depression in Adolescence and Adulthood.","authors":"Adrian E Desai Boström, Thomas Cars, Clara Hellner, Johan Lundberg","doi":"10.1111/acps.13785","DOIUrl":"https://doi.org/10.1111/acps.13785","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to estimate 5-year recurrence rates of first-episode major depressive disorder (MDD) and assess the impact of adolescence on recurrence likelihood after the first episode, compared to adults.</p><p><strong>Methods: </strong>A pre-registered retrospective cohort study that utilized epidemiological data from the Stockholm MDD Cohort (1997-2018), including all individuals registered with a depression diagnosis in Region Stockholm from 2010 to 2018. This dataset combines longitudinal information from primary and secondary care, socioeconomic data, drug dispensations, psychotherapy sessions, brain stimulation treatments, and inpatient treatment. The study included 9124 individuals (1727 adolescents aged 13-17 and 7397 adults aged 18-40) who experienced their first MDD episode between 2011 and 2012, with at least three months of remission. Propensity score weighting balanced cohorts for biological sex, socioeconomic status, depression severity, psychiatric comorbidities, and treatments.</p><p><strong>Results: </strong>The 5-year recurrence rates were 46.1% for adolescents and 49.0% for adults. The study had over 80% power to detect a minimum absolute difference in recurrence rates of approximately 5.5 percentage points. No significant difference in recurrence likelihood (p = 0.364) or time from remission to recurrence (median 379 days for adolescents, 326 days for adults, p = 0.836) was found between groups. Findings were consistent across bootstrap replicates and sensitivity analyses with extended remission periods.</p><p><strong>Conclusions: </strong>Approximately half of individuals with a first MDD episode experience recurrence within five years. Recurrence rates were higher than expected for adults but consistent with expectations for adolescents. The study underscores the need for relapse prevention from adolescence through adulthood and indicates a similar clinical course of MDD across age groups.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic Confounding of the Association Between Age at First Hormonal Contraception and Depression.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-01-02 DOI: 10.1111/acps.13774
Jessica Mundy, Alisha S M Hall, Esben Agerbo, Clara Albiñana, Jette Steinbach, Bjarni J Vilhjálmsson, Søren D Østergaard, Katherine L Musliner

Background: Previous research has shown that females who use hormonal contraception are at increased risk of developing depression, and that the risk is highest among adolescents. While this finding could reflect age-specific effects of exogenous hormones on mental health, genetic liability for mental disorders could be confounding the association. Our goal was to test the plausibility of this hypothesis by determining whether polygenic liabilities for major depressive disorder (MDD), bipolar disorder (BD), schizophrenia (SCZ), and attention deficit hyperactivity disorder (ADHD) are associated with younger age at hormonal contraception initiation.

Methods: We conducted a cohort study using data from the Danish iPSYCH2015 sub-cohort, a representative sample of people born in Denmark between May 1981 and December 2008. Polygenic scores (PGSs) for MDD, BD, SCZ, and ADHD were created using the most recent genome-wide association study meta-analyses from the Psychiatric Genomics Consortium. Associations between PGSs and hormonal contraception initiation in the following age categories: 10-14, 15-19, 20-24, and 25+ were examined via Cox regression. We examined any hormonal contraception, oral contraception, and non-oral contraception.

Results: PGS-MDD and PGS-ADHD showed the strongest associations with hormonal contraception initiation at age 10-14 (PGS-ADHD: HR = 1.21 [95% CI = 1.16-1.27], p = 6.16 x 10-18; PGS-MDD: 1.21 [1.16-1.27], p = 1.22 x 10-17). The associations then steadily decreased as age at hormonal contraception initiation increased. Both PGS-MDD and PGS-ADHD were also associated with initiation at ages 15-19, but not at 20-24 or 25+. PGS-BD and PGS-SCZ were also associated, albeit not as strongly, with initiation at age 10-14 only (PGS-BD: 1.07 [1.02-1.13], p = 6.87 × 10-3; PGS-SCZ: 1.09 [1.04-1.14], p = 8.61 × 10-4).

Conclusions and relevance: These results suggest that genetic confounding could explain some of the association between early hormonal contraception use and depression. Where possible, researchers studying this important topic should account for possible confounding by genetic liability for mental disorders.

背景:以往的研究表明,使用荷尔蒙避孕药的女性患抑郁症的风险增加,而青少年患抑郁症的风险最高。虽然这一发现可能反映了外源性激素对心理健康的年龄特异性影响,但精神障碍的遗传责任可能会混淆这种关联。我们的目标是通过确定重性抑郁症(MDD)、双相情感障碍(BD)、精神分裂症(SCZ)和注意缺陷多动障碍(ADHD)的多基因遗传责任是否与开始使用激素避孕的年龄较小有关,来检验这一假设的合理性:我们利用丹麦 iPSYCH2015 子队列的数据进行了一项队列研究,该子队列是 1981 年 5 月至 2008 年 12 月间在丹麦出生的代表性样本。我们利用精神疾病基因组学联盟(Psychiatric Genomics Consortium)最新的全基因组关联研究荟萃分析,创建了MDD、BD、SCZ和ADHD的多基因评分(PGS)。PGSs与以下年龄段开始使用激素避孕药之间存在关联:10-14岁、15-19岁、20-24岁:我们通过 Cox 回归分析了 10-14、15-19、20-24 和 25 岁以上年龄组的 PGS 与开始使用激素避孕之间的关系。我们对任何激素避孕、口服避孕和非口服避孕进行了研究:结果:PGS-MDD 和 PGS-ADHD 与 10-14 岁开始使用激素避孕的关系最为密切(PGS-ADHD:HR = 1.21 [95% CI = 1.16-1.27],p = 6.16 x 10-18;PGS-MDD:1.21 [1.16-1.27],p = 1.22 x 10-17)。随后,随着开始使用激素避孕的年龄增加,相关性逐渐降低。PGS-MDD 和 PGS-ADHD 也与 15-19 岁开始使用激素避孕有关,但与 20-24 岁或 25 岁以上开始使用激素避孕无关。PGS-BD和PGS-SCZ也与10-14岁开始使用激素避孕有关,尽管没有那么强(PGS-BD:1.07 [1.02-1.13],p = 6.87 × 10-3;PGS-SCZ:1.09 [1.04-1.14],p = 8.61 × 10-4):这些结果表明,遗传混杂因素可以解释早期使用激素避孕药与抑郁症之间的部分关联。在可能的情况下,研究人员在研究这一重要课题时,应考虑到精神疾病遗传责任可能造成的混杂因素。
{"title":"Genetic Confounding of the Association Between Age at First Hormonal Contraception and Depression.","authors":"Jessica Mundy, Alisha S M Hall, Esben Agerbo, Clara Albiñana, Jette Steinbach, Bjarni J Vilhjálmsson, Søren D Østergaard, Katherine L Musliner","doi":"10.1111/acps.13774","DOIUrl":"https://doi.org/10.1111/acps.13774","url":null,"abstract":"<p><strong>Background: </strong>Previous research has shown that females who use hormonal contraception are at increased risk of developing depression, and that the risk is highest among adolescents. While this finding could reflect age-specific effects of exogenous hormones on mental health, genetic liability for mental disorders could be confounding the association. Our goal was to test the plausibility of this hypothesis by determining whether polygenic liabilities for major depressive disorder (MDD), bipolar disorder (BD), schizophrenia (SCZ), and attention deficit hyperactivity disorder (ADHD) are associated with younger age at hormonal contraception initiation.</p><p><strong>Methods: </strong>We conducted a cohort study using data from the Danish iPSYCH2015 sub-cohort, a representative sample of people born in Denmark between May 1981 and December 2008. Polygenic scores (PGSs) for MDD, BD, SCZ, and ADHD were created using the most recent genome-wide association study meta-analyses from the Psychiatric Genomics Consortium. Associations between PGSs and hormonal contraception initiation in the following age categories: 10-14, 15-19, 20-24, and 25+ were examined via Cox regression. We examined any hormonal contraception, oral contraception, and non-oral contraception.</p><p><strong>Results: </strong>PGS-MDD and PGS-ADHD showed the strongest associations with hormonal contraception initiation at age 10-14 (PGS-ADHD: HR = 1.21 [95% CI = 1.16-1.27], p = 6.16 x 10<sup>-18</sup>; PGS-MDD: 1.21 [1.16-1.27], p = 1.22 x 10<sup>-17</sup>). The associations then steadily decreased as age at hormonal contraception initiation increased. Both PGS-MDD and PGS-ADHD were also associated with initiation at ages 15-19, but not at 20-24 or 25+. PGS-BD and PGS-SCZ were also associated, albeit not as strongly, with initiation at age 10-14 only (PGS-BD: 1.07 [1.02-1.13], p = 6.87 × 10<sup>-3</sup>; PGS-SCZ: 1.09 [1.04-1.14], p = 8.61 × 10<sup>-4</sup>).</p><p><strong>Conclusions and relevance: </strong>These results suggest that genetic confounding could explain some of the association between early hormonal contraception use and depression. Where possible, researchers studying this important topic should account for possible confounding by genetic liability for mental disorders.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Genetics to Psychosocial Functioning: Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis.
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-25 DOI: 10.1111/acps.13779
M Florencia Forte, Derek Clougher, Àlex G Segura, Gisela Mezquida, Ana Maria Sánchez-Torres, Eduard Vieta, Marina Garriga, Antonio Lobo, Ana M González-Pinto, Covadonga M Diaz-Caneja, Alexandra Roldan, Anabel Martínez-Arán, Elena de la Serna, Anna Mané, Sergi Mas, Carla Torrent, Kelly Allot, Miquel Bernardo, Silvia Amoretti

Background: Studies have shown associations between polygenic risk scores for educational attainment (PRSEA), cognitive reserve (CR), cognition, negative symptoms (NS), and psychosocial functioning in first-episode psychosis (FEP). However, their specific interactions remain unclear. This study aimed to investigate the mediating roles of CR, cognition, and NS in the relationship between PRSEA and psychosocial functioning one year after a FEP. Additionally, we sought to explore the impact of two NS subtypes on this relationship: diminished Expression (EXP-NS) and Motivation and Pleasure (MAP-NS).

Methods: A total of 138 FEP participants, predominantly male (70%), with a mean age of 24.77 years (SD = 5.29), underwent genetic, clinical, and cognitive assessments two months after study enrollment. Functioning evaluation followed at one-year follow-up. To investigate the mediating role of CR, cognition, and NS in the relationship between PRSEA and functioning, a serial mediation model was employed. Two further mediation models were tested to explore the differential impact of EXP-NS and MAP-NS. Mediation analysis was performed using the PROCESS macro version 4.1 within SPSS version 26.

Results: The serial mediation model revealed a causal chain for PRSEA > CR > cognition > NS > Functioning (β = -3.08, 95%CI [-5.73, -0.43], p = 0.023). When differentiating by type of NS, only EXP-NS were significantly associated in the casual chain (β = -0.17, 95% CI [-0.39, -0.01], p < 0.05).

Conclusions: CR, cognition and NS -specifically EXP-NS- mediate the association between PRSEA and psychosocial functioning at one-year follow-up in FEP patients. These results highlight the potential for personalized interventions based on genetic predisposition.

{"title":"From Genetics to Psychosocial Functioning: Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis.","authors":"M Florencia Forte, Derek Clougher, Àlex G Segura, Gisela Mezquida, Ana Maria Sánchez-Torres, Eduard Vieta, Marina Garriga, Antonio Lobo, Ana M González-Pinto, Covadonga M Diaz-Caneja, Alexandra Roldan, Anabel Martínez-Arán, Elena de la Serna, Anna Mané, Sergi Mas, Carla Torrent, Kelly Allot, Miquel Bernardo, Silvia Amoretti","doi":"10.1111/acps.13779","DOIUrl":"https://doi.org/10.1111/acps.13779","url":null,"abstract":"<p><strong>Background: </strong>Studies have shown associations between polygenic risk scores for educational attainment (PRS<sub>EA</sub>), cognitive reserve (CR), cognition, negative symptoms (NS), and psychosocial functioning in first-episode psychosis (FEP). However, their specific interactions remain unclear. This study aimed to investigate the mediating roles of CR, cognition, and NS in the relationship between PRS<sub>EA</sub> and psychosocial functioning one year after a FEP. Additionally, we sought to explore the impact of two NS subtypes on this relationship: diminished Expression (EXP-NS) and Motivation and Pleasure (MAP-NS).</p><p><strong>Methods: </strong>A total of 138 FEP participants, predominantly male (70%), with a mean age of 24.77 years (SD = 5.29), underwent genetic, clinical, and cognitive assessments two months after study enrollment. Functioning evaluation followed at one-year follow-up. To investigate the mediating role of CR, cognition, and NS in the relationship between PRS<sub>EA</sub> and functioning, a serial mediation model was employed. Two further mediation models were tested to explore the differential impact of EXP-NS and MAP-NS. Mediation analysis was performed using the PROCESS macro version 4.1 within SPSS version 26.</p><p><strong>Results: </strong>The serial mediation model revealed a causal chain for PRS<sub>EA</sub> > CR > cognition > NS > Functioning (β = -3.08, 95%CI [-5.73, -0.43], p = 0.023). When differentiating by type of NS, only EXP-NS were significantly associated in the casual chain (β = -0.17, 95% CI [-0.39, -0.01], p < 0.05).</p><p><strong>Conclusions: </strong>CR, cognition and NS -specifically EXP-NS- mediate the association between PRS<sub>EA</sub> and psychosocial functioning at one-year follow-up in FEP patients. These results highlight the potential for personalized interventions based on genetic predisposition.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142890602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Psychiatrica Scandinavica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1